Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q3 2025
Biocryst Pharmaceuticals (BCRX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Biocryst Pharmaceuticals (BCRX) reported revenue of $159M for the third quarter 2025 (Q3 2025), +36% from a year earlier and -2% from the quarter before. Operating margin was 18.6%, net earnings $12.9M (8.1% of revenue).
Biocryst Pharmaceuticals, Q3 2025: revenue $159M (+36% year over year), operating margin 18.6%, net earnings $12.9M, operating cash flow $41.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $159M | -2% | +36% |
| Operating profit | $29.6M | -0.7% | +285% |
| Net earnings | $12.9M | +154% | — |
| Operating cash flow | $41.6M | +0.8% | +405% |
| Free cash flow | $40.3M | -2% | +392% |
What changed
Revenue was $159.4M in Q3 2025, up 36% year over year and down 2% from the previous quarter. Product sales, net was the largest line at 99% of revenue. Product sales, net added $41.7M year over year (up 36%), 98% of the total change. Other revenues declined 58%.
Operating profit was $29.6M, a 18.6% margin (up 12.0 points year over year). Of the extra revenue versus a year earlier, 52% reached operating profit, above the 7% margin then. Total costs grew 19% against revenue growth of 36%. The fastest-growing cost line was SG&A (+28%). Net earnings were $12.9M. The effective tax rate was -6.3%.
Operating cash flow was $41.6M (up 405% year over year), 323% of net earnings. Non-cash charges added back $335K of depreciation and amortization and $18.6M of share-based compensation. Working capital and other items added $9.8M. Capital expenditures of $1.3M left free cash flow of $40.3M.
Questions
What was Biocryst Pharmaceuticals' revenue in the third quarter 2025?
Biocryst Pharmaceuticals (BCRX) reported revenue of $159M for the third quarter 2025 (Q3 2025), +36% from a year earlier and -2% from the quarter before.
Was Biocryst Pharmaceuticals profitable in the third quarter 2025?
Operating profit was $29.6M (18.6% of revenue) and net earnings $12.9M.